Stay up-to-date with the Cipla Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent ...
Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...
The VAI status is a positive surprise at a time Cipla is seeing a temporary supply challenge in Lanreotide, softness in India and competitive ... to Q2FY25 earning analysis. We retain ‘HOLD ...
However, where competition is limited, the impact would more likely be passed on. Nomura highlighted that the Cipla management comments were “largely aligned with our views . We highlighted that ...